ArticleEuropean journal of drug metabolism and pharmacokinetics2026
Population Pharmacokinetic Modeling Study of Glibenclamide in Chinese Healthy Volunteers.
Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveType 2 diabetes mellitus (T2DM) is a group of metabolic diseases characterized by chronic hyperglycemia, primarily caused by insulin resistance and/or pancreatic beta cell dysfunction. Glibenclamide, a second-generation sulfonylurea oral hypoglycemic agent, plays a crucial role in managing T2DM. Our objective was to establish a population pharmacokinetic model of glibenclamide in Chinese healthy volunteers and use this model to guide the adjustment of individualized dosage regimens.
methodsWe collected 476 concentration observations of glibenclamide from 20 Chinese healthy volunteers in a phase I clinical trial. A fundamental three-compartment pharmacokinetic model with instantaneous zero-order absorption and linear elimination was developed using the first-order conditional estimation method by NONMEM software. A covariate model was developed by screening for relevant covariates based on the base model. Internal validation of the final model was performed using visual predictive checks and bootstrap methods. The reference standard for the final model was used to assess the quality of the simulated doses.
resultsA PopPK model of glibenclamide in Chinese healthy volunteers was successfully established. Age significantly impacted the apparent distribution volume of the central compartment. Validation results indicate that the final model is stable. Simulation results indicate that the model has good goodness of fit.
conclusionsThe established population model accurately represents the pharmacokinetics of glibenclamide in Chinese healthy volunteers and based on this model, can be further extrapolated to inform individualized medication strategies for glibenclamide in the treatment of T2DM in the future.
Indexed as
Identifiers
42384301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.